Analysis of the key themes driving private equity deal activity reveals that digitalization accounted for five pharmaceutical deals announced in Q3 2024, worth a total value of $1.5bn. The $1.5bn institutional buy-out (ibo) PetIQ by Bansk Group was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, digitalization-related deal activity increased by 74900% in Q3 2024 compared with the previous quarter’s total of $2m and rose by 6242% as compared to Q3 2023. Related deal volume increased by 150% in Q3 2024 versus the previous quarter and was 400% higher than in Q3 2023.
The top-ranked financial advisors supporting these private equity deals in 9M 2024 were Deloitte NSE; GREENHILL; Groupe BPCE with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these private equity deals in 9M 2024 were Davis Polk & Wardwell; Cooley; Gomez-Acebo & Pombo Abogados with 2, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.